|Videos|September 12, 2016

Managing Patients at High Risk for Antibiotic-resistant Infections

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, describes how hospital clinicians can identify and treat patients at highest risk for contracting antibiotic-resistant infections.

John D'Angelo, MD, senior vice president, executive director of Emergency Medicine Services at Northwell Health, describes how hospital clinicians can identify and treat patients at highest risk for contracting antibiotic-resistant infections.

Interview Transcript (slightly modified for readability)

“There are screenings that are done, swabs on admitted patients that are at higher risk, to identify folks so that you could stop the spread [of these antibiotic-resistant pathogens], but with the folks living in nursing homes, with all [of that] there’s a lot of opportunity for these things to spread and we just have to be aware when folks have the various, whether it’s MRSA or Vancomycin-resistant enterococcus or things of that nature, we have to be aware, and cohort them appropriately and use the appropriate precautions to keep it from spreading.

What we also do is, we keep in our electronic medical record, that history, once we know [that] they have it and then the subsequent visits will be flagged and the precautions can start much earlier in their encounter in subsequent visits. We don’t take them off of that flagging process until we’ve had several documented negative screens in the future.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.